Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Energy Budgets and Reproductive Strategies00:51

Energy Budgets and Reproductive Strategies

Organisms must balance energy intake with the energy required for growth, maintenance, and reproduction. These trade-offs result in a variety of survivorship and reproductive strategies, including semelparity and iteroparity. Semelparous species reproduce only once in their lifetime, often investing most available resources into that single reproductive event. Iteroparous species, by contrast, reproduce multiple times over their lifetimes, typically allocating fewer resources to any single...
Synthetic Biology02:55

Synthetic Biology

Synthetic biology is an interdisciplinary science that involves using principles from disciplines such as engineering, molecular biology, cell biology, and systems biology. It involves remodeling existing organisms from nature or constructing completely new synthetic organisms for applications such as protein or enzyme production, bioremediation, value-added macromolecule production, and the addition of desirable traits to crops, to name a few.
Golden rice
Golden rice is a genetically modified...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Threats to Biodiversity01:50

Threats to Biodiversity

There have been five major extinction events throughout geological history, resulting in the elimination of biodiversity, followed by a rebound of species that adapted to the new conditions. In the current geological epoch, the Holocene, there is a sixth extinction event in progress. This mass extinction has been attributed to human activities and is thus provisionally called the Anthropocene. In 2019 the human population reached 7.7 billion people and is projected to comprise 10 billion by...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two old hands and the new new thing. Interview by Rob Cunningham.

Health affairs (Project Hope)·2001
Same author

Transcript: remarks on Medicare reform from the AMA House of Delegates' annual meeting.

Journal of the Mississippi State Medical Association·1995
Same author

NewtCare.

Hospitals & health networks·1995
Same author

LTC financing: is it time for change?

Provider (Washington, D.C.)·1992
Same author

A message and a challenge.

Journal of the Medical Association of Georgia·1990
Same author

In praise of PACs.

Journal of the Medical Association of Georgia·1983

Related Experiment Video

Updated: Jul 12, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
12:38

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Published on: July 19, 2007

SCIENCE PRIORITIES: An Opportunities-Based Science Budget.

N Gingrich

    Science (New York, N.Y.)
    |September 6, 2007
    PubMed
    Summary

    This article proposes an opportunities-based budget for federal research and development funding. It advocates for prioritizing funding based on the potential of scientific discoveries rather than budget increase percentages.

    Area of Science:

    • Science and Technology Policy
    • Federal Research Funding
    • Innovation Economics

    Background:

    • Current federal research and development (R&D) funding debates often focus on budget increase percentages.
    • This approach may not effectively allocate resources to the most promising scientific opportunities.

    Purpose of the Study:

    • To introduce and advocate for an "opportunities-based budget" framework for federal R&D funding.
    • To shift the discourse from funding levels to the strategic allocation of resources based on scientific potential.

    Main Methods:

    • Conceptual analysis of current R&D funding strategies.
    • Proposal of a new budgeting paradigm focused on "opportunities".

    Main Results:

    More Related Videos

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
    16:26

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

    Published on: August 20, 2007

    Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology
    09:55

    Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology

    Published on: September 28, 2022

    Related Experiment Videos

    Last Updated: Jul 12, 2026

    Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
    12:38

    Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

    Published on: July 19, 2007

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
    16:26

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

    Published on: August 20, 2007

    Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology
    09:55

    Bridging the Technology Divide in the COVID-19 Era: Using Virtual Outreach to Expose Middle and High School Students to Imaging Technology

    Published on: September 28, 2022

  • Identifies limitations in percentage-based R&D budget discussions.
  • Presents an alternative framework for aligning funding with scientific promise.

    • Conclusions:

    • Rethinking federal R&D funding through an opportunities-based approach is crucial.
    • This strategic allocation will better support future scientific discoveries and societal benefit.